Tetrahedral-Framework Nucleic Acid Loaded with MicroRNA-155 Enhances Immunocompetence in Cyclophosphamide-Induced Immunosuppressed Mice by Modulating Dendritic Cells and Macrophages
Source abstract
Abstract
Nanomaterials are often used as immunomodulators because they can be tailored by a controllable process. In this work, a complex based on a tetrahedral framework nucleic acid delivery system and MicroRNA-155, known as T-155, is synthesized for the modulation of immunosuppression. In vivo, T-155 ameliorated spleen and thymus damage and hematopoiesis suppression in cyclophosphamide-induced immunosuppressed mice by promoting T-cell proliferation to resist oxidative stress. In vitro, T-155 induced immature dendritic cells (DCs) to differentiate into mature DCs by the ERK1/2 pathway and converted M0 macrophages (Mφ) into the M1 type by the NF-κB pathway to enhance the surveillance capabilities of antigen-presenting cells. The experimental results suggest that T-155 has therapeutic potential as an immunomodulator for immunosuppression.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China
Sichuan Provincial Engineering Research Center of Oral Biomaterials, Chengdu, Sichuan 610041, China
Funding
Ministry of Science and Technology of the People's Republic of China · Natural Science Foundation of Sichuan Province · Department of Science and Technology of Sichuan Province · National Natural Science Foundation of China · West China Hospital of Stomatology, Sichuan University · Sichuan Province Youth Science and Technology Innovation Team
References (61)
Show source-provided references
1. 10.3390/biom1205073710.3390/biom12050737 ↗
2. 10.1093/cid/ciaa86310.1093/cid/ciaa863 ↗
3. 10.1007/978-1-4419-0981-7_110.1007/978-1-4419-0981-7_1 ↗
4. Bhasin A. · J. Assoc. Physicians India · 2018 · 66 · 90
5. 10.1038/d41573-021-00002-010.1038/d41573-021-00002-0 ↗
6. 10.1056/NEJMe203068710.1056/NEJMe2030687 ↗
7. 10.1189/jlb.110777510.1189/jlb.1107775 ↗
8. 10.1189/jlb.031212510.1189/jlb.0312125 ↗
9. 10.1055/s-0034-139734410.1055/s-0034-1397344 ↗
10. 10.1016/j.cej.2022.14039910.1016/j.cej.2022.140399 ↗
11. 10.1089/jir.2018.015510.1089/jir.2018.0155 ↗
12. 10.1016/j.intimp.2021.10818810.1016/j.intimp.2021.108188 ↗
13. 10.1155/2021/887485410.1155/2021/8874854 ↗
14. 10.1126/science.114122910.1126/science.1141229 ↗
15. 10.1126/science.113925310.1126/science.1139253 ↗
16. 10.3390/ph1103006210.3390/ph11030062 ↗
17. 10.3390/ijms22241336010.3390/ijms222413360 ↗
18. 10.1002/adma.20220428710.1002/adma.202204287 ↗
19. 10.1002/adma.20220173110.1002/adma.202201731 ↗
20. 10.1016/j.bioactmat.2020.12.02710.1016/j.bioactmat.2020.12.027 ↗
21. 10.1002/advs.20220205810.1002/advs.202202058 ↗
22. 10.1002/adma.20220251310.1002/adma.202202513 ↗
23. 10.1021/acsami.1c2065710.1021/acsami.1c20657 ↗
24. 10.1038/s41392-020-0173-310.1038/s41392-020-0173-3 ↗
25. 10.1021/acs.nanolett.2c0002510.1021/acs.nanolett.2c00025 ↗
26. 10.1021/acsnano.1c0962610.1021/acsnano.1c09626 ↗
27. 10.1021/acs.nanolett.1c0500310.1021/acs.nanolett.1c05003 ↗
28. 10.1039/c9nr07171g10.1039/c9nr07171g ↗
29. 10.1021/acsami.9b1064510.1021/acsami.9b10645 ↗
30. 10.1016/j.lfs.2020.11758010.1016/j.lfs.2020.117580 ↗
31. 10.1007/978-1-0716-0795-4_110.1007/978-1-0716-0795-4_1 ↗
32. 10.1586/erv.10.17410.1586/erv.10.174 ↗
33. 10.1136/bmj.h98810.1136/bmj.h988 ↗
34. 10.1038/icb.2011.9610.1038/icb.2011.96 ↗
35. 10.1016/j.bioactmat.2021.06.00310.1016/j.bioactmat.2021.06.003 ↗
36. 10.1021/acsami.1c1615110.1021/acsami.1c16151 ↗
37. 10.1002/adma.20210960910.1002/adma.202109609 ↗
38. 10.1016/j.bioactmat.2021.11.03110.1016/j.bioactmat.2021.11.031 ↗
39. 10.1021/acsami.0c2300510.1021/acsami.0c23005 ↗
40. 10.1016/j.gene.2012.12.00910.1016/j.gene.2012.12.009 ↗
41. 10.1080/03008207.2018.148335610.1080/03008207.2018.1483356 ↗
42. 10.1038/nrclinonc.2009.14610.1038/nrclinonc.2009.146 ↗
43. 10.1038/nbt133210.1038/nbt1332 ↗
44. 10.3390/molecules2310266810.3390/molecules23102668 ↗
45. 10.1016/j.redox.2017.08.00310.1016/j.redox.2017.08.003 ↗
46. 10.1155/2016/263670110.1155/2016/2636701 ↗
47. 10.4049/jimmunol.090213310.4049/jimmunol.0902133 ↗
48. 10.1182/blood.V93.5.163410.1182/blood.V93.5.1634 ↗
49. 10.1042/bst2022027110.1042/bst20220271 ↗
50. 10.1073/pnas.090913310710.1073/pnas.0909133107 ↗
51. 10.1155/2020/175179310.1155/2020/1751793 ↗
52. 10.1038/sj.bjp.070433410.1038/sj.bjp.0704334 ↗
53. 10.1074/jbc.275.5.311410.1074/jbc.275.5.3114 ↗
54. 10.1073/pnas.070361010410.1073/pnas.0703610104 ↗
55. 10.1016/j.cell.2006.05.03510.1016/j.cell.2006.05.035 ↗
56. 10.1002/jcp.2642910.1002/jcp.26429 ↗
57. 10.1101/cshperspect.a00165110.1101/cshperspect.a001651 ↗
58. 10.1016/j.tibs.2004.11.00910.1016/j.tibs.2004.11.009 ↗
59. 10.1016/j.intimp.2020.10721810.1016/j.intimp.2020.107218 ↗
60. 10.1007/s13105-018-0629-x10.1007/s13105-018-0629-x ↗
61. 10.7754/Clin.Lab.2016.16051110.7754/Clin.Lab.2016.160511 ↗